GOSSAMER BIO, INC. Basic Shares Outstanding (Weighted Average)
GOSSAMER BIO, INC. (GOSS) reported Basic Shares Outstanding (Weighted Average) of 320.01 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-13
- GOSSAMER BIO, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 320.01M shares, a 40.80% increase year-over-year.
- GOSSAMER BIO, INC. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 234.14M shares, a 3.23% increase year-over-year.
- GOSSAMER BIO, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 231.99M shares, a 2.37% increase year-over-year.
- GOSSAMER BIO, INC. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 227.98M shares, a 0.72% increase year-over-year.
- GOSSAMER BIO, INC. weighted average number of shares outstanding, basic for fiscal 2025 was 228.52M shares, a 1.01% increase from fiscal 2024.
- GOSSAMER BIO, INC. weighted average number of shares outstanding, basic for fiscal 2024 was 226.23M shares, a 48.23% increase from fiscal 2023.
- GOSSAMER BIO, INC. weighted average number of shares outstanding, basic for fiscal 2023 was 152.62M shares, a 80.46% increase from fiscal 2022.
- GOSSAMER BIO, INC. weighted average number of shares outstanding, basic for fiscal 2022 was 84.57M shares, a 13.00% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 320.01M shares 10-Q · filed 2026-08-13 | 277.31M shares 10-Q · filed 2026-08-13 | 262.05M shares derived: average of 3 quarters · filed 2026-08-13 | 253.53M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 234.14M shares 10-Q · filed 2026-05-15 | 233.06M shares derived: average of 2 quarters · filed 2026-05-15 | 231.37M shares derived: average of 3 quarters · filed 2026-05-15 | 230.35M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | 231.99M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 229.99M shares derived: average of 2 quarters · filed 2026-03-17 | 229.08M shares derived: average of 3 quarters · filed 2026-08-13 | 228.52M shares 10-K · filed 2026-03-17 |
| 2025-09-30 | 227.98M shares 10-Q · filed 2025-11-05 | 227.63M shares derived: average of 2 quarters · filed 2026-08-13 | 227.36M shares 10-Q · filed 2025-11-05 | 227.17M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | 227.28M shares 10-Q · filed 2026-08-13 | 227.05M shares 10-Q · filed 2026-08-13 | 226.90M shares derived: average of 3 quarters · filed 2026-08-13 | 226.76M shares derived: average of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | 226.82M shares 10-Q · filed 2026-05-15 | 226.71M shares derived: average of 2 quarters · filed 2026-05-15 | 226.59M shares derived: average of 3 quarters · filed 2026-05-15 | 226.50M shares derived: average of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | 226.61M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 226.48M shares derived: average of 2 quarters · filed 2026-03-17 | 226.39M shares derived: average of 3 quarters · filed 2026-03-17 | 226.23M shares 10-K · filed 2026-03-17 |
| 2024-09-30 | 226.35M shares 10-Q · filed 2025-11-05 | 226.28M shares derived: average of 2 quarters · filed 2025-11-05 | 226.10M shares 10-Q · filed 2025-11-05 | 226.13M shares derived: average of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | 226.22M shares 10-Q · filed 2025-08-05 | 225.98M shares 10-Q · filed 2025-08-05 | 226.06M shares derived: average of 3 quarters · filed 2026-03-17 | 217.76M shares derived: average of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | 225.74M shares 10-Q · filed 2025-05-15 | 225.97M shares derived: average of 2 quarters · filed 2026-03-17 | 214.94M shares derived: average of 3 quarters · filed 2026-03-17 | 185.07M shares derived: average of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | 226.21M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | 209.55M shares derived: average of 2 quarters · filed 2026-03-17 | 171.51M shares derived: average of 3 quarters · filed 2026-03-17 | 152.62M shares 10-K · filed 2026-03-17 |
| 2023-09-30 | 192.88M shares 10-Q · filed 2024-11-07 | 144.17M shares derived: average of 2 quarters · filed 2024-11-07 | 128.09M shares 10-Q · filed 2024-11-07 | 119.40M shares derived: average of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | 95.45M shares 10-Q · filed 2024-08-12 | 95.16M shares 10-Q · filed 2024-08-12 | 94.90M shares derived: average of 3 quarters · filed 2025-03-13 | 93.97M shares derived: average of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | 94.87M shares 10-Q · filed 2024-05-07 | 94.63M shares derived: average of 2 quarters · filed 2025-03-13 | 93.48M shares derived: average of 3 quarters · filed 2025-03-13 | 89.28M shares derived: average of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | 94.39M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | 92.78M shares derived: average of 2 quarters · filed 2025-03-13 | 87.41M shares derived: average of 3 quarters · filed 2025-03-13 | 84.57M shares 10-K · filed 2025-03-13 |
| 2022-09-30 | 91.18M shares 10-Q · filed 2023-11-09 | 83.92M shares derived: average of 2 quarters · filed 2023-11-09 | 81.30M shares 10-Q · filed 2023-11-09 | 79.84M shares derived: average of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | 76.67M shares 10-Q · filed 2023-08-08 | 76.28M shares 10-Q · filed 2023-08-08 | 76.05M shares derived: average of 3 quarters · filed 2024-03-05 | 75.79M shares derived: average of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | 75.89M shares 10-Q · filed 2023-05-09 | 75.75M shares derived: average of 2 quarters · filed 2024-03-05 | 75.50M shares derived: average of 3 quarters · filed 2024-03-05 | 75.29M shares derived: average of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | 75.60M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | 75.30M shares derived: average of 2 quarters · filed 2024-03-05 | 75.09M shares derived: average of 3 quarters · filed 2024-03-05 | 74.84M shares 10-K · filed 2024-03-05 |
| 2021-09-30 | 75.00M shares 10-Q · filed 2022-11-03 | 74.84M shares derived: average of 2 quarters · filed 2022-11-03 | 74.59M shares 10-Q · filed 2022-11-03 | 74.25M shares derived: average of 4 quarters · filed 2023-03-17 |
| 2021-06-30 | 74.67M shares 10-Q · filed 2022-08-09 | 74.38M shares 10-Q · filed 2022-08-09 | 74.00M shares derived: average of 3 quarters · filed 2023-03-17 | 73.56M shares derived: average of 4 quarters · filed 2023-03-17 |
| 2021-03-31 | 74.09M shares 10-Q · filed 2022-05-10 | 73.67M shares derived: average of 2 quarters · filed 2023-03-17 | 73.20M shares derived: average of 3 quarters · filed 2023-03-17 | 71.55M shares derived: average of 4 quarters · filed 2023-03-17 |
| 2020-12-31 | 73.25M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | 72.75M shares derived: average of 2 quarters · filed 2023-03-17 | 70.70M shares derived: average of 3 quarters · filed 2023-03-17 | 68.51M shares 10-K · filed 2023-03-17 |
| 2020-09-30 | 72.25M shares 10-Q · filed 2021-11-08 | 69.42M shares derived: average of 2 quarters · filed 2021-11-08 | 66.93M shares 10-Q · filed 2021-11-08 | |
| 2020-06-30 | 66.60M shares 10-Q · filed 2021-08-09 | 64.25M shares 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | 61.89M shares 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 54.74M shares 10-K · filed 2022-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |